inspect molecule / ahzantive
Ahzantive
Aflibercept-Mrbb o--o \/ /\ o--o
Aflibercept-Mrbb is the active ingredient anchor for this record. Use the ingredient name before comparing brand, country, or pharmacy prices.
active moietyAflibercept-Mrbb
administration routeIntravitreal
price comparison status2 snapshots
safety signal rating54 / 100
Vascular Endothelial Growth Factor Inhibitor [EPC]openFDA NDC seedopenFDA NDC40 mg/mL
price index
Typical Class Estimates
⚠ Verified price snapshots are queued for this brand/package. Showing typical market estimates based on the drug class: Vascular Endothelial Growth Factor Inhibitor [EPC].
$24.50USvsCA$14.20CA
- US Typical Class Average · US$24.50
30 tablets · acquisition-reference · Molecule Index Class Benchmark ↗
- CA Typical Class Average · CACA$14.20
30 tablets · formulary-benefit-price · Molecule Index Class Benchmark ↗
Prices are source-backed snapshots, not medical advice, insurance adjudication, or guaranteed checkout totals.
query trend --id 4078 --12m
Price Trend Index
Deterministic trailing 12-month value delta index for this active ingredient class.
Falling3M: -1.9%12M: -7.4%
Jul 2025Jun 2026
Jan 2026$25.34
Feb 2026$25.23
Mar 2026$24.97
Apr 2026$24.86
May 2026$24.75
Jun 2026$24.49
01 / chemistryValorum Biologics, LLC
Ingredient Breakdown
active moietyAflibercept-Mrbb
formulationIntravitreal Vascular Endothelial Growth Factor Inhibitor [EPC]
mechanism of action
Vascular Endothelial Growth Factor Inhibitor [EPC]
available strengths
40 mg/mL
02 / ingredientsexcipients
Excipients / Maker Notes
- Not enriched yet from label source.
Manufacturer Notes
- This record is normalized from the openFDA NDC seed. Add DailyMed label extraction before treating manufacturer details as complete.
03 / safetyclinical signals
Steps To Take Safely
- Use the ingredient name as the anchor before comparing any brand or pharmacy listing.
- Read the official label for route-specific directions, contraindications, and storage.
- Ask a clinician or pharmacist before substituting products across countries or formulations.
- Treat severe or rapidly worsening symptoms as urgent, especially after starting or changing a medicine.
Side-Effect Signals
- label-specific reactions
- allergic reaction
- interaction risk
- dose/formulation confusion
- urgent symptoms require clinician review
Summary of index signals. Not active medical advice. Consult official labels and clinicians.
$ grep ingredient --same
Same Ingredient Sibling Records
No same-ingredient sibling appears in the current indexed records yet.